Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Agenus and GSK tout positive Phase 3 data for RSV vaccine

By Brian Buntz | June 10, 2022

Agenus/GSKImmuno-oncology firm Agenus (Nasdaq:AGEN) and its partner GSK (NYSE:GSK) have announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 Phase 3 trial of an experimental respiratory syncytial virus (RSV) vaccine.

RSV infects most children before the age of 2. Some 75,000 to 125,000 children are hospitalized as a result of the virus annually, according to data from the National Institute of Allergy and Infectious Diseases.

But RSV can also pose a risk to older adults, especially those with chronic conditions, as the CDC noted.

The Agenus and GSK study focused on adults at least 60 years of age.

The analysis of the Phase 3 trial was the first to show a statistically significant and clinically meaningful efficacy in older adults.

Agenus and GSK  note that the AReSVi 006 study exceeded its primary endpoint without observing any unexpected safety concerns.

The companies hope to file regulatory submissions in the second half of 2022.

“The need for vaccines offering long-lasting efficacy and scalable production processes has been amplified by the current pandemic,” said Dr. Garo H. Armen, Agenus CEO, in a news release.

The AReSVi 006 vaccine candidate makes use of the QS-21 STIMULON saponin-based adjuvant, which is derived from  the soapbark tree Quillaja saponaria Molina.

The popular Shingrix vaccine Shingrix uses the same adjuvant.

Agenus operates a subsidiary known as SaponiQx focused on the sustainable manufacturing of QS-21 STIMULON.

AGEN shares dipped 10.98% to $1.46 while GSK shares were up 1.77% to $43.80.

A number of other companies, including Moderna, are also developing RSV vaccines.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: Agenus, GSK, respiratory syncytial virus, RSV
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Bavarian Nordic
U.S. purchases more monkeypox vaccine doses from Bavarian Nordic
covid-19 vaccine
FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
Pfizer-BioNTech
Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government
Icosavax
Icosavax shares positive early results for VLP vaccine candidate against RSV

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50